尿素II受体调节与1,3,4-三二胺-2-one四甲模仿剂
Xiaozheng Wei1, Sitan Diarra2, Antoine Douchez1,2
1Département de Chimie, Université de Montréal, 1375 Ave. Thérèse-Lavoie-Roux, Montréal, Québec, Canada H2V 0B3.
Journal of medicinal chemistry
|October 6, 2023
概括
新的子胺化合物选择性调节尿素II (UII) 和尿素II相关 (URP) 在尿素II受体 (UT) 的活性. 这些选择性调节器是了解UII和URP在疾病中的独特生物学作用的宝贵工具.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- 尿素II受体 (UT) 调节器对于区分内源性联体尿素II (UII) 和尿素II相关 (URP) 的作用至关重要.
- 了解UI和URP的独特生物学作用对于疾病病因学研究至关重要.
- 之前的研究集中在 urocontrin ([Bip4]URP) 的 γ-转变形状模仿上.
研究的目的:
- 设计,合成和评估新型的1,3,4-二二衍生物作为UT的选择性调节剂.
- 研究这些化合物的结构-活性关系,以模仿Phe-Bip-Lys-Tyr四烯序列.
- 阐明UT信号通路的药理学复杂性.
主要方法:
- 设计和合成8-替代的1,3,4-三二-2-.
- 检查生物活性,包括血管收缩试验.
- 通过Gα13,βarr1和Gα<0xE1><0xB5><0xA1>通路进行偏差信号的评估.
主要成果:
- 班佐特里亚泽皮农的5位和8位的微妙修改导致了偏差信号传输.
- 特定的类似物 (例如,17b-d) 选择性地激活了Gα13和βarr1通路,而没有Gα<0xE1><0xB5><0xA1>信号.
- 一些三级胺基 (15d,17d) 选择性地抑制了IIII诱导的血管收缩,不影响URP反应.
结论:
- 三氨碳胺是剖析UT受体药理学的有效工具.
- 这些化合物使UII和URP信号的分化成为可能.
- 这些发现为开发基于选择性UT调节的向治疗提供了基础.
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
764
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
764
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
679
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
679
01:25Antihypertensive Drugs: Direct Renin Inhibitors
657
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
657
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
445
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
445
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
180
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
180